The importance of chemotherapy-induced peripheral neuropathy (CIPN) to clinicians and patients

Mary Anne Tanay, cancer nurse at King’s College London, UK, discusses some of the findings of a thematic synthesis of available research on chemotherapy-induced peripheral neuropathy (CIPN). She talks about how CIPN is sidelined by both patients and clinicians as getting the maximum anti-tumor effects is prioritized. This is problematic as CIPN could be irreversible. She also discusses the experiences of patients who develop CIPN. The effects can often be severe, undermining patient’s ability to do everday activities such as driving or typing, impacting their social, leisure, family and work roles, potentially having significant financial implications. She highlights the lack of studies that measure patient experience of chemotherapy and peripheral neuropathy in the UK. The next steps thus are find out specifically how the UK performs in helping, supporting and informing patients with CIPN. Recorded at the 2016 Annual Meeting of the Oncology Nursing Society (ONS), held in Brighton, UK.

Share this video